LIFD LFTD PARTNERS INC.
Pharmaceutical Preparations · OTC · SEC CIK 1391135 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-15.9%
TTM net income YoY-53,461.9%
TTM EPS YoY—
Revenue 3-yr CAGR-14.3%
Net income 3-yr CAGR—
Margins
Gross margin8.3%
Operating margin-27.9%
Net margin-108.9%
FCF margin2.1%
EBITDA margin-26.8%
Returns
ROE-164.2%
ROA-127.1%
ROIC (approx.)-38.3%
Asset turnover1.17x
Leverage & solvency
Liabilities / assets55.7%
Debt / equity0.00x
Current ratio1.63x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.02x
Accruals ratio-130.2%
Payout ratio—
Capex / revenue0.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $36.92M | $37.33M |
| Cost of revenue | $24.30M | $24.57M |
| Gross profit | $12.62M | $12.75M |
| Operating income | $913,208 | -$773,464 |
| Pretax income | -$24.43M | -$2.38M |
| Income tax | $432,824 | -$524,425 |
| Net income | -$24.86M | -$1.86M |
| EBITDA | $1.47M | -$252,833 |
| EPS (basic) | -1.68 | -0.13 |
| EPS (diluted) | -1.68 | -0.13 |
| Weighted avg. shares (diluted) | 14.82M | 14.80M |
| Banking | ||
| Deposits | $1.00M | $1.00M |
| Balance sheet | ||
| Cash & equivalents | $1.77M | $3.15M |
| Receivables | $2.53M | $2.66M |
| Inventory | $10.96M | $9.32M |
| Current assets | $15.69M | $17.23M |
| PP&E, net | $2.27M | $2.70M |
| Goodwill | $0 | $23.09M |
| Intangibles | $0 | — |
| Total assets | $19.27M | $47.62M |
| Current liabilities | $5.16M | $6.39M |
| Total liabilities | $6.64M | $10.12M |
| Shareholders' equity | $12.63M | $37.50M |
| Shares outstanding | 14.82M | 14.82M |
| Cash flow statement | ||
| Operating cash flow | $1.32M | -$960,067 |
| Capital expenditure | $121,639 | $313,763 |
| Free cash flow | $1.20M | -$1.27M |
| Investing cash flow | -$121,639 | -$479,574 |
| Financing cash flow | -$2.58M | -$770,951 |
| Depreciation & amortization | $552,877 | $520,631 |
| Share buybacks | $0 | $240,240 |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.